trending Market Intelligence /marketintelligence/en/news-insights/trending/RM-xYhNgYULgk-QdVdhf5A2 content esgSubNav
In This List

Bristol-Myers' Opdivo gets US FDA approval for colorectal cancer

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Bristol-Myers' Opdivo gets US FDA approval for colorectal cancer

The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co.'s Opdivo in another cancer indication.

The therapy can now be used to fight a certain type of metastatic colorectal cancer that progressed after receiving fluoropyrimidine, oxaliplatin and irinotecan.

The indication was approved under accelerated approval supported by overall response rate and duration of response in a phase 2 trial.

Opdivo is approved for a number of cancers, including lung cancer.